- 18 February, 2011A CytoPathfinder-Affiliated R&D Project Wins a Government Sponsorship
- 28 October, 2010FANCL Unveils a High Performance Anti-aging Cosmetic Material Co-developed with CytoPathfinder
- 20 August, 2010CytoPathfinder and Takeda Team Up to Expand the Horizons of a Transfection Technology
- 29 October, 2009
On 29th October 2009 the tri-party collaboration project, "Identification of off-label effects of FDA-approved drugs on aberrant splicing in myotonic dystrophy in cultured patient fibroblasts and model mice" amongst Nagoya University, Okayama University and CytoPathfinder was selected by Japan Science and Technology Agency as one of research outcome optimum incubation, A-STEP FS stage of potential pharmaceutical research.
CytoPathfinder will contribute to further expansion of its research activities in many therapeutic areas from now on. - 14 August, 2009 NEDO* grants subsidy to CytoPathfinder’s development of Cellular Pharmacogenomics (PGx) system for study on profiling of hepatotoxic compounds. (*New Energy and Industrial Technology Development Organization)
- 13 July, 2009 CytoPathfinder moves its wet lab to AIST* Tokyo Waterfront from Kiba. (*National Institute of Advanced Industrial Science and Technology)
- 1 July, 2009 CytoPathfinder begins collaboration with AIST on Cellular PGx.
- 29 June, 2009 CytoPathfinder acquired PGXIS Ltd. and its wholly-owned UK subsidiary PGXIS Ltd., a pharmacogenomic specified company.
- 28 October, 2008 Takeda Pharmaceutical; the latest recipient of CytoPathfinder's transfection technology
